Zacks Analyst Blog Highlights: Lions Gate Entertainment, Amylin Pharmaceuticals, Amylin Pharmaceuticals, Eli Lilly, Alkermes and Novo Nordisk http://www.zacks.com/

CHICAGO, Nov 12, 2010 (BUSINESS WIRE) -- Zacks.com Analyst Blog features: Lions Gate Entertainment Corporation (NYSE: LGF), Amylin Pharmaceuticals (Nasdaq: AMLN), Eli Lilly (NYSE: LLY), Alkermes, Inc. (Nasdaq: ALKS) and Novo Nordisk (NYSE: NVO).

Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=4579 Here are highlights from Thursday's Analyst Blog: Lions Gate Delivers a Loss Lions Gate Entertainment Corporation (NYSE: LGF) recently delivered second-quarter 2011 results, with its bottom line swinging to a loss hurt by the rise in theatrical marketing costs. Distribution of four theatrical releases compared with two in the prior-year quarter led to an increased expenditure on marketing.

The company posted a quarterly loss of 11 cents a share, reflecting a sharp drop from the earnings of 26 cents in the prior-year quarter. The quarter under review excludes a loss on extinguishment of debt. The analysts covered by Zacks had expected Lions Gate to deliver a loss of 10 cents a share. On a reported basis, including one-time items, the quarterly loss came in at 22 cents a share.

Total revenue for the quarter climbed 24.7% to $456.3 million from the prior-year quarter, reflecting an increase in Theatrical, International and Television Production revenues. Total revenue also outpaced the Zacks Consensus Revenue Estimate of $422 million.

Lions Gate hinted that adjusted EBITDA plunged 55% to $24.3 million from the prior-year quarter. However, it reflected a sharp improvement from an EBITDA loss of $13.7 million in first-quarter 2011. EBITDA margin for the quarter contracted to 5.3% from 14.7% in the year-ago quarter.

Wider Loss at Amylin Amylin Pharmaceuticals (Nasdaq: AMLN) reported a net loss of 31 cents per share in the third quarter of 2010, three cents below the Zacks Consensus Estimate but well above the year-earlier loss of 19 cents. Lower revenues resulted in the wider loss. Revenues of $156.1 million missed the Zacks Consensus Estimate of $159 million.

Quarterly Details Total revenues for the quarter declined 19.5% mainly due to lower net product sales. Quarterly revenues consisted of $154.0 million in product sales and $2.1 million in collaborative revenues, which consist of the amortization of upfront fees received under the company's collaboration agreements with Eli Lilly (NYSE: LLY) and Takeda.

Product revenues comprised $132.4 million in sales of Byetta (exenatide) and $21.6 million in sales of Symlin. Both Byetta and Symlin revenues declined on a sequential as well as year-over-year basis. While Byetta revenues declined 10% from the year-earlier period, Symlin declined 0.9% from the year-earlier period.

On a sequential basis, Byetta and Symlin declined 5.9% and 0.9%, respectively.

Byetta revenues have been under pressure over the past few quarters due to pancreatitis fears associated with the use of the drug. Amylin is looking to return Byetta to growth now that it is armed with a US Food and Drug Administration (FDA) approval for the use of the drug as a first-line monotherapy for type II diabetes patients. Amylin also intends to expand the label so that Byetta can be used in combination with basal insulin. The company intends to seek approval for the label expansion by year-end.

However, we believe the next few quarters will remain challenging from a growth standpoint. Fears of pancreatitis and new-found fears of glucagon-like peptide-1 (GLP-1) molecules like exenatide potentially causing C-cell malignant carcinoma of the thyroid could keep a lid on growth.

Meanwhile, Amylin's increased promotional effort behind Symlin should help prescription growth for the candidate to rebound. The company could also strike a partnership deal for Symlin in non-US territories later this year.

Selling, general and administrative (SG&A) expenses for the quarter declined to $72.7 million from $80.1 million in the year-earlier period. The decrease was mainly due to efficiencies driven by the company's reduced cost structure and lower sales force expenses.

Research and development (R&D) expenses increased to $48.4 million in the reported quarter from $35.3 million reported in the prior-year period. The increase primarily reflects higher expenses incurred on Bydureon.

Update on Bydureon On the third quarter call, Amylin provided an update on its lead pipeline candidate, Bydureon (a once-weekly version of Byetta), which received a second complete response letter (CRL) from the FDA. Amylin and its partners, Eli Lilly and Alkermes, Inc. (Nasdaq: ALKS), were looking to get Bydureon approved for the treatment of type II diabetes.

The latest CRL, which came a few days ahead of the FDA action date, was a complete surprise. At the time of issuing the first CRL, the FDA had not asked the companies to conduct additional studies. At that time, the FDA had only asked for additional information that was subsequently submitted by the companies.

However, in its latest CRL, the FDA has asked the companies to conduct a thorough QT (tQT) study. We believe the FDA may have asked for this study based on the recent concerns regarding the cardiovascular safety profile of diabetes drugs.

The agency has also asked Amylin and its partners to submit data from the DURATION-5 study, which was conducted to compare the safety and efficacy of Bydureon versus Byetta.

On its earnings call, Amylin said that data from the DURATION program shows that there is no increased risk of cardiovascular complications due to QT prolongation, arrhythmias or conduction disorders associated with the use of Bydureon. Amylin intends to meet with the FDA as early as possible so as to fix the design of the required tQT study.

The company is looking to file a response to the CRL by the end of 2011. At that time, Amylin expects the response to be treated as a Class II resubmission which means that a final response from the FDA could be out in six months. Bydureon is currently under review in the EU; a response could come in the first half of 2011.

In the meantime, Amylin is working on a once-monthly formulation of Bydureon.

The candidate is currently in a phase II dose-finding study. The company is also developing a pen device for Bydureon.

As far as other pipeline candidates are concerned, Amylin intends to submit the clinical and non-clinical sections of a new drug application for the use of metreleptin for the treatment of severe lipodystrophy by year end.

Neutral on Amylin We currently have a Neutral recommendation on Amylin, which is supported by a Zacks #3 Rank (short-term "Hold" rating). The delay in the approval of Bydureon is a major jolt for Amylin. With currently marketed products, Byetta and Symlin, lagging expectations, Amylin had a lot riding on the timely approval of Bydureon.

Currently, we do not expect Bydureon to hit the market before the second half of 2012. Once launched, Bydureon will face stiff competition from Novo Nordisk's (NYSE: NVO) Victoza.

Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5514.

About Zacks Equity Research Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks.

Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5516 About Zacks Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leonard Zacks. As a PhD in mathematics Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=4580.

Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.

Follow us on Twitter: http://twitter.com/ZacksResearch Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.

SOURCE: Zacks.com CONTACT: Zacks.com Mark Vickery Web Content Editor 312-265-9380 Visit: www.zacks.com Copyright Business Wire 2010 -0- KEYWORD: United States

North America

Illinois INDUSTRY KEYWORD: Professional Services

Finance